GM-K562

GM-K562 is a genetically modified human chronic myelogenous leukemia (CML) cell line (K-562) engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF). The cells are lethally irradiated to prevent proliferation and used as an immunotherapeutic vaccine adjuvant. When admixed with autologous tumor cells or administered alone, the paracrine secretion of GM-CSF recruits dendritic cells to the vaccination site. These dendritic cells capture tumor antigens and present them to T-cells in draining lymph nodes, thereby stimulating anti-tumor immune responses. The approach has been studied primarily as a component of whole-cell vaccines for hematologic malignancies such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), and follicular lymphoma—often after allogeneic stem cell transplantation[1][3][5][6][8]. Clinical trials have demonstrated that this strategy is generally safe and can induce biologic activity against residual disease.

Brand names

GVAX

Other names

GM-K562GM-K-562GM-K 562K562/GM-CSF